Grants and Contributions:
Title:
Validation of a unique High Precision Cold Plasma Device as adjuvant for breast cancer radiotherapy
Agreement Number:
905621
Agreement Value:
$50,000.00
Agreement Date:
Apr 2, 2018 - Mar 29, 2019
Description:
This project assesses a unique device as a potential adjuvant for breast cancer radiotherapy to enhance the selective kill of breast cancer cells in order to reduce cancer recurrence.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Montreal, Quebec, CA H4A 2T7
Reference Number:
172-2018-2019-Q1-905621
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
819165614
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 57 days.
Amendment Date
Jan 31, 2019
Recipient's Legal Name:
NexPlasmaGen Incorporée
Federal Riding Name:
Notre-Dame-de-Grâce--Westmount
Federal Riding Number:
24053
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
339110
Amendments: